Published on 10 Apr 2024 on Zacks via Yahoo Finance

Vincerx (VINC) Tumbles on Results From Cancer Therapy Study

Shares of Vincerx Pharma VINC plunged around 65% in pre-market trading on Tuesday after management announced preliminary results from early-stage clinical studies evaluating its pipeline candidates. These results were presented at the American Society of Cataract and Refractive Surgery (ASCRS).

At the ASCRS, Vincerx reported initial data from a phase I study evaluating VIP236, its investigational small molecule drug conjugate (SMDC), in 15 patients with metastatic tumors who have exhausted all standard therapy options. Early data from this study showed that seven patients achieved objective stable disease, including tumor reduction. Management also claimed that treatment with the drug was well-tolerated with no dose-limiting toxicities (DLTs).

Wall Street was not impressed with these results. Analysts at Leerink Partners pointed out that though the patients did achieve stable disease, the results were ‘lacking RECIST responses.’ The Leerink analysts claimed that the results posted by the company were ‘early’ and ‘potentially below investor expectations.’